Oncotelic Therapeutics Inc
oncotelic.comOncotelic Therapeutics Inc (OTC: OTLC) is a clinical-stage oncology company that develops cancer therapeutics and an AI-enabled pharmaceutical research platform. The company generates no product revenue; it is funded through debt and equity issuances while advancing a pipeline of drug candidates and a proprietary AI platform called PDAOAI. Oncotelic operates primarily through a joint venture with GMP Bio, to which it transferred the bulk of its pipeline costs as of April 2022. Its lead drug candidates include OT-101, an inhibitor of the TGF-beta system, and CA4P (Fosbretabulin), a vascular disrupting agent being studied in combination with checkpoint inhibitors. As of December 31, 2025, the company held approximately $0.1 million in cash, carried approximately $11.9 million in short-term debt including accrued interest, and reported an accumulated deficit of approximately $38 million since inception, partially offset by a FY2025 fair-value gain on its GMP Bio investment of approximately $365.4 million (per the 10-K filed April 15, 2026).
Products & Services
OT-101: a TGF-beta inhibitor in clinical trials for multiple cancers, including pancreatic cancer, developed through the GMP Bio joint venture. CA4P (Fosbretabulin/Fosbretabul): a vascular disrupting agent with FDA Rare Pediatric Disease designation, studied in combination with checkpoint inhibitors such as Ipilimumab. PDAOAI: a proprietary AI-enabled knowledge platform built around a TGF-beta-centric biomedical corpus of over 100,000 curated abstracts, designed for regulatory documentation, biomarker discovery, and scientific traceability in pharmaceutical R&D. The company is also developing an integrated AI and robotics platform in partnership with TechForce to automate GMP-compliant manufacturing workflows.
Revenue Model
Pre-revenue clinical-stage model. No product sales disclosed in the filing. Operations are financed through debt issuances and equity raises. A significant non-cash gain of approximately $365.4 million was recorded in FY2025 from a fair-value revaluation of the company's ownership interest in the GMP Bio joint venture.
Customers & Markets
End markets are oncology patients across cancer indications including pancreatic cancer, glioblastoma, breast cancer, and pediatric melanoma. No commercial customers disclosed. The company is pre-commercial.
Geographic Exposure
Clinical trials being evaluated in the United States and China through the GMP Bio joint venture, per the 10-K filed April 15, 2026. No commercial geographic revenue mix disclosed.
Financial Snapshot
Loading...
